Julia L. Hurwitz, PhD
Julia L. Hurwitz, PhD

Julia L. Hurwitz, PhD

Member, St. Jude Faculty



PhD – Johns Hopkins University, Baltimore, Maryland (1981)

Research Interests

Selected Publications

Jones BG, Penkert RR, Xu B, Fan Y, Neale G, Gearhart PJ, Hurwitz JL. Binding of estrogen receptors to switch sites and regulatory elements in the immunoglobulin heavy chain locus of activated B cells suggests a direct influence of estrogen on antibody expression. Mol Immunol 77:97-102, 2016. doi: 10.1016/j.molimm.2016.07.015. [Epub ahead of print]

Sealy RE, Surman SL, Vogel P, Hurwitz JL. Antibody-secreting cells in respiratory tract tissues in the absence of eosinophils as supportive partners. Int Immunol, 2016. pii: dxw035. [Epub ahead of print]

Hankins JS, Penkert RR, Lavoie P, Tang L, Sun Y, Hurwitz JL. Original Research: Parvovirus B19 infection in children with sickle cell disease in the hydroxyurea era. Exp Biol Med (Maywood) 241(7):749-54, 2016.

Hurwitz JL, Tuomanen E. Unveiling Unexpected Immune Activities Induced by Your Pneumococcal Vaccine. MBio 7(1):e00137-16, 2016.

Hurwitz JL, Penkert RR, Xu B, Fan Y, Partridge JF, Maul RW, Gearhart PJ. Hotspots for Vitamin-Steroid-Thyroid Hormone Response Elements Within Switch Regions of Immunoglobulin Heavy Chain Loci Predict a Direct Influence of Vitamins and Hormones on B Cell Class Switch Recombination. Viral Immunol 29(2):132-6, 2016.

Surman SL, Penkert RR, Jones BG, Sealy RE, Hurwitz JL. Vitamin Supplementation at the Time of Immunization with a Cold-Adapted Influenza Virus Vaccine Corrects Poor Mucosal Antibody Responses in Mice Deficient for Vitamins A and D. Clin Vaccine Immunol 23(3):219-27, 2016.

Russell CJ, Hurwitz JL. Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses. Expert Rev Vaccines 15(2):189-200, 2016.

Sealy RE, Jones BG, Surman SL, Branum K, Howlett NM, Flynn PM, Hurwitz JL. Murine Monoclonal Antibodies for Antigenic Discrimination of HIV-1 Envelope Proteins. Viral Immunol 29(1):64-70, 2016.

Penkert RR, Surman SL, Jones BG, Sealy RE, Vogel P, Neale G, Hurwitz JL. Vitamin A deficient mice exhibit increased viral antigens and enhanced cytokine/chemokine production in nasal tissues following respiratory virus infection despite the presence of FoxP3+ T cells. Int Immunol 28(3):139-52, 2016.

Jones BG, Oshansky CM, Bajracharya R, Tang L, Sun Y, Wong SS, Webby R, Thomas PG, Hurwitz JL. Retinol binding protein and vitamin D associations with serum antibody isotypes, serum influenza virus-specific neutralizing activities and airway cytokine profiles. Clin Exp Immunol 183(2):239-47, 2016.

Burke CW, Li M, Hurwitz JL, Vogel P, Russell CJ. Relationships among dissemination of primary parainfluenza virus infection in the respiratory tract, mucosal and peripheral immune responses, and protection from reinfection: a noninvasive bioluminescence-imaudy. J Virol 89(7):3568-83, 2015.

Adderson E, Branum K, Sealy RE, Jones BG, Surman SL, Penkert R, Freiden P, Slobod KS, Gaur AH, Hayden RT, Allison K, Howlett N, Utech J, Allay J, Knight J, Sleep S, Meagher MM, Russell CJ, Portner A, Hurwitz JL. Safety and immunogenicity of an intranasal Sendai virus-based human parainfluenza virus type 1 vaccine in 3- to 6-year-old children. Clin Vaccine Immunol 22(3):298-303, 2015.

Zhan X, Slobod KS, Jones BG, Sealy RE, Takimoto T, Boyd K, Surman S, Russell CJ, Portner A, Hurwitz JL. Sendai virus recombinant vaccine expressing a secreted, unconstrained respiratory syncytial virus fusion protein protects against RSV in cotton rats. Int Immunol 27(5):229-36, 2015.

Kim YI, DeVincenzo JP, Jones BG, Rudraraju R, Harrison L, Meyers R, Cehelsky J, Alvarez R, Hurwitz JL. Respiratory syncytial virus human experimental infection model: provenance, production, and sequence of low-passaged memphis-37 challenge virus. PLoS One 9(11):e113100, 2014.

Jones BG, Sealy RE, Surman SL, Portner A, Russell CJ, Slobod KS, Dormitzer PR, DeVincenzo J, Hurwitz JL. Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model. Vaccine 32(26):3264-73, 2014.

Surman SL, Jones BG, Sealy RE, Rudraraju R, Hurwitz JL. Oral retinyl palmitate or retinoic acid corrects mucosal IgA responses toward an intranasal influenza virus vaccine in vitamin A deficient mice. Vaccine 32(22):2521-4, 2014.

Surman SL, Jones BG, Rudraraju R, Sealy RE, Hurwitz JL. Intranasal administration of retinyl palmitate with a respiratory virus vaccine corrects impaired mucosal IgA response in the vitamin A-deficient host. Clin Vaccine Immunol 21(4):598-601, 2014.

Rudraraju R, Jones BG, Surman SL, Sealy RE, Thomas PG, Hurwitz JL. Respiratory tract epithelial cells express retinaldehyde dehydrogenase ALDH1A and enhance IgA production by stimulated B cells in the presence of vitamin A. PLoS One 9(1):e86554, 2014.

Rosenberger CM, Podyminogin RL, Askovich PS, Navarro G, Kaiser SM, Sanders CJ, McClaren JL, Tam VC, Dash P, Noonan JG, Jones BG, Surman SL, Peschon JJ, Diercks AH, Hurwitz JL, Doherty PC, Thomas PG, Aderem A. Characterization of innate responses to influenza virus infection in a novel lung type I epithelial cell model. J Gen Virol 95(Pt 2):350-62, 2014.

Rudraraju R, Sealy RE, Surman SL, Thomas PG, Dayton BH, Hurwitz JL. Non-random lymphocyte distribution among virus-infected cells of the respiratory tract. Viral Immunol 26(6):378-84, 2013.

Jones BG, Hayden RT, Hurwitz JL. Inhibition of primary clinical isolates of human parainfluenza virus by DAS181 in cell culture and in a cotton rat model. Antiviral Res 100(2):562-6, 2013. 

Rudraraju R, Jones BG, Sealy R, Surman SL, Hurwitz JL. Respiratory Syncytial Virus: Current Progress in Vaccine Development. Viruses 5:577-594, 2013.

Sealy RE, Webby RJ, Crumpton JC, Hurwitz JL. Differential localization and function of antibody forming cells responsive to inactivated or live-attenuated influenza virus vaccines. International Immunology 25:183-195, 2013.

Surman SL, Rudraraju R, Sealy R, Jones BG, Hurwitz JL. Vitamin A deficiency disrupts vaccine-induced antibody forming cells and the balance of IgA/IgG isotypes in the upper and lower respiratory tract. Viral Immunol 25:341-344, 2012.

Rudraraju R, Surman S, Jones B, Sealy R, Woodland D, Hurwitz JL. Reduced frequencies and heightened CD103 expression among virus-induced CD8+ T cells in the respiratory tract airways of vitamin A-deficient mice. Clin Vaccine Immunol 19: 757-765, 2012.

Jones BG, Sealy RE, Zhan X, Freiden PJ, Surman SL, Blanchard JL, Hurwitz JL. UV-inactivated vaccinia virus (VV) in a multi-envelope DNA-VV-protein (DVP) HIV-1 vaccine protects macaques from lethal challenge with heterologous SHIV. Vaccine 30: 3188-3195, 2012.

Show More

Jones BG, Sealy R, Rudraraju R, Traina-Dorge V, Finneyfrock B, Cook A, Takimoto T, Portner A,Hurwitz JL. Sendai virus-based RSV vaccine protects African green monkeys from RSV infection.Vaccine 30: 959-968, 2011.

Hurwitz JL. Respiratory syncytial virus vaccine development. Expert Review Vaccines 10: 1415-1433, 2011.

Surman SL, Rudraraju R, Thomas P, Woodland D, Dash, P, Hurwitz JL. Clonally related T cells rapidly seed diffuse nasal associated lymphoid tissue, lower airways and lungs following respiratory virus infection. J Immunol 187: 835-841, 2011.

Burke,CW, Mason JN, Surman SL, Jones BG, Dalloneau E, Hurwitz JL, Russell CJ. Illumination of parainfluenza virus infection and transmission in living mice reveals a tissue-specific dichotomy in the respiratory tract. Plos Pathogens 7: e1002134, 1-13, 2011.

Rudraraju R, Surman SL, Jones BG, Sealy R, Woodland D, Hurwitz JL. Phenotypes and functions of persistent Sendai virus-induced antibody forming cells and CD8+ T cells in diffuse nasal-associated lymphoid tissue typify lymphocyte responses of the gut. NIHMS 265052. Virology 410:429-436, 2011.

Surman SL, Brown SA, Jones BG, Woodland DL, Hurwitz JL. Clearance of HIV-1 envelope recombinant Sendai virus by CD4+ T cells and interferon-gamma without B-cells, CD8+ T-cells or perforin. AIDS Res Hum Retroviruses 26:783-793, 2010. PMCID#PMC2932556

Sealy R, Jones BG, Surman SL, Hurwitz JL. Robust IgA and IgG-producing antibody forming cells in the diffuse NALT and lungs of Sendai virus-vaccinated cotton rats associate with rapid protection against human parainfluenza virus-type 1. Vaccine 28:6749-6756, 2010. PMCID#PMC2950074

Brown SA, Surman SL, Sealy R, Jones BG, Slobod KS, Branum K, Lockey TD, Howlett N, Freiden P, Flynn P, Hurwitz JL. Heterologous prime-boost HIV-1 vaccination regimens in pre-clinical and clinical trials. Viruses 2:(2)435-467, 2010. PMCID#PMC28855973

Heslop HE, Slobod K, Pule M, Hale G, Rousseau A, Smith CA, Bollard CM, Liu H, Wu J, Rochester R, Amrolia P, Hurwitz J, Brenner MK, Rooney CM. Long term outcome of EBV specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115:925-935, 2010. PMCID# PMC2817637

Sealy R, Jones BG, Surman SL, Hurwitz JL. The Dead Cell: A Potent Escort for HIV-1 Trans-Infection. AIDS Res Hum Retroviruses 25:1123-1128, 2009. NIHMS#131921

Hurwitz JL, Shenep JL, Russell CJ, Portner A. Development of Sendai virus-based vaccines to prevent pediatric respiratory virus infections. Procedia in Vaccinology 1:41-44, 2009.

Sealy R, Zhan X, Lockey TD, Martin L, Blanchard J, Traina-Dorge V, Hurwitz JL. SHIV infection protects against heterologous pathogenic SHIV challenge in macaques: A gold-standard for HIV-1 vaccine development? Current HIV Research 7:497-5-3, 2009.

Surman SL, Sealy R, Jones BG, Hurwitz JL. HIV-1 vaccine design: Harnessing diverse lymphocytes to conquer a diverse pathogen (NIHMS #89672). Human Vaccines 5:268-271, 2009.

Jones B, Zhan X, Mishin V, Slobod KS, Surman S, Russell CJ, Portner A, Hurwitz JL. Human PIV-2 recombinant Sendai Virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3 and RSV. Vaccine 27:1848-1857, 2009. NIHMS#124065

Sealy R, Slobod K, Flynn P, Branum K, Surman S, Jones B, Freiden P, Lockey T, Howlett N, Hurwitz JL. Pre-clinical and clinical development of a multi-envelope DNA-Virus-Protein (D-V-P) HIV-1 vaccine (PMCID# PMC2649747). International Reviews Immunol 28:49-68, 2009. PMCID#2649747

Hurwitz JL. Development of recombinant Sendai virus vaccines for prevention of human parainfluenza virus and respiratory syncytial virus infections. Pediatr Inf Dis J 27:S126-128, 2008.

Zhan X, Slobod KS, Krishnamurthy S, Luque LE, Takimoto T, Jones B, Surman S, Russell CJ, Portner A, Hurwitz JL. Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections.Vaccine 26:3480-3488, 2008.

Lockey TD, Zhan X, Sample CE, Hurwitz JL. Developing an Epstein-Barr virus vaccine: Eliciting responses toward lytic and latent proteins with a cocktail vaccine approach. Front Bioscience13:5916-5927, 2008.

Sealy R, Chaka WS, Surman S, Brown S, Cresswell P, Hurwitz JL.Target peptide sequence within infectious HIV-1 does not ensure envelope-specific T-helper cell re-activation: influences of cysteine protease and gamma-interferon induced thiol reductase activities. Clin Vaccine Immunol 15:713-719, 2008.

Hurwitz JL, Lockey T, Jones B, Freiden P, Sealy R, Coleman J, Howlett N, Branum K, Slobod KS. First Phase I clinical safety trial of an HIV-1 subtype D gp140 envelope protein vaccine: Immunogenicity induced among all study participants. AIDS 22:149-158, 2008.

Hurwitz JL, Zhan X, Brown SA, Bonsignori M, Stambas J, Lockey TD, Sealy R, Surman S, Freiden P, Jones B, Martin L, Blanchard J, Slobod KS. HIV-1 vaccine development: Tackling virus diversity with a multi-envelope cocktail. Front Bioscience 13:609-620, 2008.

Last update: August 2016